Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Total Liabilities (2020 - 2025)

Universe Pharmaceuticals' Total Liabilities history spans 6 years, with the latest figure at $13.2 billion for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 41.32% to $13.2 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $13.2 billion, a 41.32% decrease, with the full-year FY2025 number at $13.2 billion, down 41.32% from a year prior.
  • Total Liabilities hit $13.2 billion in Q3 2025 for Universe Pharmaceuticals, down from $22.5 billion in the prior quarter.
  • Over the last five years, Total Liabilities for UPC hit a ceiling of $22.5 billion in Q3 2024 and a floor of -$35.3 billion in Q3 2022.
  • Historically, Total Liabilities has averaged $68.8 million across 5 years, with a median of $22.9 million in 2021.
  • Biggest five-year swings in Total Liabilities: plummeted 152442.21% in 2022 and later soared 163124.63% in 2024.
  • Tracing UPC's Total Liabilities over 5 years: stood at $23.2 million in 2021, then plummeted by 152442.21% to -$35.3 billion in 2022, then surged by 100.04% to $13.8 million in 2023, then soared by 163124.63% to $22.5 billion in 2024, then plummeted by 41.32% to $13.2 billion in 2025.
  • Business Quant data shows Total Liabilities for UPC at $13.2 billion in Q3 2025, $22.5 billion in Q3 2024, and $22.7 million in Q1 2024.